Our analysis of EGFR/MAP2K1/MTOR/TEAD1/YAP1 within the TME revealed that the gene signature is significantly hypomethylated and exhibited high copy number alterations with a consequent negative impact on the levels of active CTL within the TME of NSCLC (Figure 4). The gene discussed is MAP2K1; the disease is non-small cell lung carcinoma.